October 4, 2012 — The burden of brain amyloid in nondemented elderly persons is lower among those who carry a newly identified gene for late-onset Alzheimer's disease (AD) compared with noncarriers, ...

A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Lowering the transcription factor PU.1 reprograms microglia into a neuroprotective, lymphoid-like state that compacts amyloid ...

Disrupted sleep patterns in Alzheimer’s disease may be more than a symptom—they could be a driving force. Researchers at ...

The experimental pill ALZ-801 slowed memory decline by 50% and reduced brain shrinkage in early Alzheimer's patients with ...

It elucidates the series of events involving the dissociation, misfolding and aggregation of TTR proteins, resulting in the formation of amyloid fibrils. It also higlights various therapeutic ...

Shares of Intellia Therapeutics (NTLA) crashed ~28% in the premarket on Friday after the company disclosed that a patient who ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...